Back to search

University of Crete (UOC)

Correlation of recurrence risk with detectable genetic alterations, microbiota, circulating tumor cells, and circulating tumor DNA in patients with resectable stage II and stage III colorectal cancer

Abstract

dc:description

Colorectal cancer (CRC) is one of the most common causes of morbidity and a leading cause of cancer-related mortality worldwide. Modern lege artis management of CRC patients necessitates the development of novel prognostic methods that complement and may even surpass the traditional tumor-node-metastasis (TNM, 8th edition) staging system. According to current data, post-operative chemotherapy is recommended for all patients with stage III and high-risk stage II CRC. Nevertheless, 20-25% of these patients will eventually experience disease recurrence, primarily in the form of metastatic disease, and only 15-20% of those receiving adjuvant chemotherapy will survive as a direct result of the treatment. Concerning the toxicity of chemotherapy, its costs, the increasing CRC incidence, and the limited resources of healthcare systems, the need for structured risk assessment to evaluate recurrence potential is both urgent and essential. This PhD research investigates the composition of the gut microbiome and the presence of microbial DNA fragments in the bloodstream of early-stage CRC patients, focusing on their potential use as prognostic markers. Through an in-depth analysis, the study aims to bridge gaps in understanding the role of the gut microbiome and microbial translocation in CRC evolution and the outcomes of this specific patient population. The study enrolled 142 early-stage CRC patients and 91 healthy controls, analyzing their fecal and blood samples using advanced techniques such as 16S rRNA sequencing and targeted microbial DNA amplification. Data processing employed robust bioinformatics pipelines for clustering, diversity metrics calculation, and taxonomic profiling. CRC patients exhibited significant microbial dysbiosis compared to controls, characterized by reduced alpha diversity and distinct beta diversity profiles. Taxonomic analyses identified unique microbial taxa in CRC patients, suggesting their potential as biomarkers. Specific taxa, including Porphyromonas and Finegoldia, were exclusively associated with CRC, supporting their relevance in disease pathology. Remarkably, microbial DNA fragments, including 16S rRNA and fungal-specific 5.8S rRNA, were detected in patient blood samples, indicating possible microbial translocation. Correlation analyses linked these fragments with distinct microbial clusters, providing insights into their role in CRC subtyping and disease progression. This phenomenon highlights a potential pathway for systemic inflammation and its implications for CRC prognosis. The findings advance understanding of the influence of the gut microbiota on CRC evolution and propose a framework for its integration into clinical practice. By identifying microbial biomarkers and leveraging microbial DNA as non-invasive prognostic tools, this research advocates for personalized treatment strategies. Such approaches could minimize unnecessary interventions for patients with favorable prognoses and enhance treatment efficacy for high-risk individuals. Despite its contributions, the study recognizes limitations, including the cross-sectional design and modest sample size, necessitating validation in larger, international, and longitudinal cohorts. Future investigations should unravel the mechanistic interplay between microbiota, systemic inflammation, and CRC progression, paving the way for microbiome-informed oncology. This project casts light on the transformative potential of the gut microbiome in CRC management, presenting a compelling case for its inclusion in precision oncology. Through innovative methodologies, the study contributes to enhancing the accuracy of CRC prognosis, ultimately reducing healthcare burdens and improving both survival and quality of life outcomes in alignment with the principles of precision medicine.

Degree

thesis:*
Grantor dc:publisher
University of Crete (UOC)
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Koulouris, Andreas
  • Κουλούρης, Ανδρέας

Subjects

dc:subject × 22

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/59263

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Koulouris, Andreas; Κουλούρης, Ανδρέας. Correlation of recurrence risk with detectable genetic alterations, microbiota, circulating tumor cells, and circulating tumor DNA in patients with resectable stage II and stage III colorectal cancer. University of Crete (UOC), 2025. http://hdl.handle.net/10442/hedi/59263